An increased reporting of shigellosis cases, mainly caused by Shigella sonnei, among travellers returning from Cabo Verde has been ongoing in the European Union/European Economic Area (EU/EEA), the United Kingdom (UK), and the United States (US) since September 2022. This outbreak evolved rapidly during November and December 2022.
This document assesses the risk of further spread of S. sonnei amongst MSM and in the broader population in EU/EEA countries, resulting from the current increase in extensively-drug resistant S. sonnei infections.
In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.
In April 2019, Finland reported false-negative or equivocal results in patients tested for Chlamydia trachomatis (CT) using Aptima Combo 2 Assay (Hologic) (AC2).
As of 30 August 2018, Algeria has reported 74 confirmed cholera cases from six northern and coastal areas of the country. This is the first cholera outbreak reported in Algeria in more than 20 years.
The production of this rapid risk assessment was triggered by a report by the Czech Republic of two travelassociated cases of cholera from Zanzibar (Tanzania) and the cholera epidemics in the Horn of Africa and the Gulf of Aden.
The occurrence of shigellosis among refugees is not unexpected because shigellosis is endemic in the countries they originate from, as well as in some of the countries they travel through.
This risk assessment was triggered by two cases of paralytic poliomyelitis in children, caused by circulating vaccine-derived poliovirus type 1 (cVDPV1) in Ukraine during June and July 2015.
This rapid risk assessment examines the implications of the temporary recommendations for EU Member States and assesses whether the developments leading to the declaration of a PHEIC represent an increased risk of WPV importation to Member States of the European Union.
The confirmed circulation of wild-type poliovirus (WPV) in Israel and the outbreak of poliomyelitis in Syria mean that there is a high risk the disease will be reintroduced into the EU/EEA.